In the world of science, getting accurate and consistent results is key. Thanks to artificial intelligence and automation advancements, achieving this is now easier than ever. Take, for example, the APAS® PharmaQC product from Australian MedTech company LBT Innovations (ASX: LBT). Using AI technology, microbiologists can analyse multiple culture plates. By removing the variability often
Read More
Adelaide-based medtech company LBT Innovations (ASX: LBT) is moving nicely along the path to commercialise their flagship product, presenting clinical data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which will be held online over the weekend. The ECCMID represents the largest global conference for clinical microbiology and is a unique opportunity
Read More
LBT Innovations (ASX: LBT) has this morning announced the sale of two of their AI pathology instruments. The Adelaide based med tech company is a leader in medical technology automation through the use of artificial intelligence. Their flagship product is the APAS® Independence. The Automated Plate Assessment System (APAS®) technology integrates AI to automate culture
Read More
Adelaide-based medical technology company LBT Innovations (ASX: LBT) is lining up distributors in the lucrative US healthcare market for their pathology screening tech which is driven by artificial intelligence to maximise testing throughput in labs, providing healthcare professionals with accurate results faster. The Automated Plate Assessment System (APAS®) is a pathology AI device which automates
Read More